guest ::
| Home > Publications database > Peptides Derived From Insulin Granule Proteins Are Targeted by CD8+ T Cells Across MHC Class I Restrictions in Humans and NOD Mice. > print |
| Home > Publications database > Peptides Derived From Insulin Granule Proteins Are Targeted by CD8+ T Cells Across MHC Class I Restrictions in Humans and NOD Mice. > print |
| 001 | 167227 | ||
| 005 | 20240229123235.0 | ||
| 024 | 7 | _ | |2 doi |a 10.2337/db20-0013 |
| 024 | 7 | _ | |2 pmid |a pmid:32928873 |
| 024 | 7 | _ | |2 ISSN |a 0012-1797 |
| 024 | 7 | _ | |2 ISSN |a 1939-327X |
| 024 | 7 | _ | |a altmetric:90329746 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2021-00212 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Azoury, Marie Eliane |b 0 |
| 245 | _ | _ | |a Peptides Derived From Insulin Granule Proteins Are Targeted by CD8+ T Cells Across MHC Class I Restrictions in Humans and NOD Mice. |
| 260 | _ | _ | |a Alexandria, Va |b Assoc. |c 2020 |
| 336 | 7 | _ | |2 DRIVER |a article |
| 336 | 7 | _ | |2 DataCite |a Output Types/Journal article |
| 336 | 7 | _ | |0 PUB:(DE-HGF)16 |2 PUB:(DE-HGF) |a Journal Article |b journal |m journal |s 1612168957_12223 |
| 336 | 7 | _ | |2 BibTeX |a ARTICLE |
| 336 | 7 | _ | |2 ORCID |a JOURNAL_ARTICLE |
| 336 | 7 | _ | |0 0 |2 EndNote |a Journal Article |
| 500 | _ | _ | |a Division of Developmental Immunology |
| 520 | _ | _ | |a The antigenic peptides processed by β-cells and presented through surface HLA class I molecules are poorly characterized. Each HLA variant (e.g., the most common being HLA-A2 and HLA-A3) carries some peptide-binding specificity. Hence, features that, despite these specificities, remain shared across variants may reveal factors favoring β-cell immunogenicity. Building on our previous description of the HLA-A2/A3 peptidome of β-cells, we analyzed the HLA-A3-restricted peptides targeted by circulating CD8+ T cells. Several peptides were recognized by CD8+ T cells within a narrow frequency (1-50/106), which was similar in donors with and without type 1 diabetes and harbored variable effector/memory fractions. These epitopes could be classified as conventional peptides or neoepitopes, generated either via peptide cis-splicing or mRNA splicing (e.g., secretogranin-5 [SCG5]-009). As reported for HLA-A2-restricted peptides, several epitopes originated from β-cell granule proteins (e.g., SCG3, SCG5, and urocortin-3). Similarly, H-2Kd-restricted CD8+ T cells recognizing the murine orthologs of SCG5, urocortin-3, and proconvertase-2 infiltrated the islets of NOD mice and transferred diabetes into NOD/scid recipients. The finding of granule proteins targeted in both humans and NOD mice supports their disease relevance and identifies the insulin granule as a rich source of epitopes, possibly reflecting its impaired processing in type 1 diabetes. |
| 536 | _ | _ | |0 G:(DE-HGF)POF3-314 |a 314 - Tumor immunology (POF3-314) |c POF3-314 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |2 NLM Chemicals |a Chromogranins |
| 650 | _ | 7 | |2 NLM Chemicals |a Epitopes |
| 650 | _ | 7 | |2 NLM Chemicals |a HLA-A3 Antigen |
| 650 | _ | 7 | |2 NLM Chemicals |a Insulin |
| 650 | _ | 7 | |2 NLM Chemicals |a Neuroendocrine Secretory Protein 7B2 |
| 650 | _ | 7 | |2 NLM Chemicals |a RNA, Messenger |
| 650 | _ | 7 | |2 NLM Chemicals |a Ucn3 protein, mouse |
| 650 | _ | 7 | |2 NLM Chemicals |a Urocortins |
| 650 | _ | 2 | |2 MeSH |a Adult |
| 650 | _ | 2 | |2 MeSH |a Alternative Splicing |
| 650 | _ | 2 | |2 MeSH |a Animals |
| 650 | _ | 2 | |2 MeSH |a CD8-Positive T-Lymphocytes |
| 650 | _ | 2 | |2 MeSH |a Case-Control Studies |
| 650 | _ | 2 | |2 MeSH |a Chromogranins: genetics |
| 650 | _ | 2 | |2 MeSH |a Chromogranins: metabolism |
| 650 | _ | 2 | |2 MeSH |a Computer Simulation |
| 650 | _ | 2 | |2 MeSH |a Data Mining |
| 650 | _ | 2 | |2 MeSH |a Diabetes Mellitus, Type 1: genetics |
| 650 | _ | 2 | |2 MeSH |a Diabetes Mellitus, Type 1: metabolism |
| 650 | _ | 2 | |2 MeSH |a Epitopes |
| 650 | _ | 2 | |2 MeSH |a Female |
| 650 | _ | 2 | |2 MeSH |a Gene Expression Regulation |
| 650 | _ | 2 | |2 MeSH |a HLA-A3 Antigen |
| 650 | _ | 2 | |2 MeSH |a Humans |
| 650 | _ | 2 | |2 MeSH |a Insulin |
| 650 | _ | 2 | |2 MeSH |a Male |
| 650 | _ | 2 | |2 MeSH |a Mice |
| 650 | _ | 2 | |2 MeSH |a Mice, Inbred NOD |
| 650 | _ | 2 | |2 MeSH |a Neuroendocrine Secretory Protein 7B2: genetics |
| 650 | _ | 2 | |2 MeSH |a Neuroendocrine Secretory Protein 7B2: metabolism |
| 650 | _ | 2 | |2 MeSH |a Protein Binding |
| 650 | _ | 2 | |2 MeSH |a RNA, Messenger: genetics |
| 650 | _ | 2 | |2 MeSH |a Urocortins: genetics |
| 650 | _ | 2 | |2 MeSH |a Urocortins: metabolism |
| 650 | _ | 2 | |2 MeSH |a Young Adult |
| 700 | 1 | _ | |a Tarayrah, Mahmoud |b 1 |
| 700 | 1 | _ | |a Afonso, Georgia |b 2 |
| 700 | 1 | _ | |a Pais, Aurore |b 3 |
| 700 | 1 | _ | |a Colli, Maikel L |b 4 |
| 700 | 1 | _ | |a Maillard, Claire |b 5 |
| 700 | 1 | _ | |a Lavaud, Cassandra |b 6 |
| 700 | 1 | _ | |0 0000-0002-4549-699X |a Alexandre-Heymann, Laure |b 7 |
| 700 | 1 | _ | |a Gonzalez-Duque, Sergio |b 8 |
| 700 | 1 | _ | |a Verdier, Yann |b 9 |
| 700 | 1 | _ | |a Vinh, Joelle |b 10 |
| 700 | 1 | _ | |0 P:(DE-He78)d2f9dbffa7b9a979f9bc4d81e769497e |a Pinto, Sheena |b 11 |
| 700 | 1 | _ | |a Buus, Soren |b 12 |
| 700 | 1 | _ | |0 0000-0003-3287-6309 |a Dubois-Laforgue, Danièle |b 13 |
| 700 | 1 | _ | |0 0000-0002-1017-1845 |a Larger, Etienne |b 14 |
| 700 | 1 | _ | |a Beressi, Jean-Paul |b 15 |
| 700 | 1 | _ | |a Bruno, Graziella |b 16 |
| 700 | 1 | _ | |0 0000-0003-2453-5889 |a Eizirik, Decio L |b 17 |
| 700 | 1 | _ | |a You, Sylvaine |b 18 |
| 700 | 1 | _ | |0 0000-0002-9846-8861 |a Mallone, Roberto |b 19 |
| 773 | _ | _ | |0 PERI:(DE-600)1501252-9 |a 10.2337/db20-0013 |g Vol. 69, no. 12, p. 2678 - 2690 |n 12 |p 2678 - 2690 |t Diabetes |v 69 |x 1939-327X |y 2020 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:167227 |p VDB |
| 910 | 1 | _ | |0 I:(DE-588b)2036810-0 |6 P:(DE-He78)d2f9dbffa7b9a979f9bc4d81e769497e |a Deutsches Krebsforschungszentrum |b 11 |k DKFZ |
| 913 | 1 | _ | |0 G:(DE-HGF)POF3-314 |1 G:(DE-HGF)POF3-310 |2 G:(DE-HGF)POF3-300 |3 G:(DE-HGF)POF3 |4 G:(DE-HGF)POF |a DE-HGF |b Gesundheit |l Krebsforschung |v Tumor immunology |x 0 |
| 914 | 1 | _ | |y 2020 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0100 |2 StatID |a JCR |b DIABETES : 2018 |d 2020-08-29 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0200 |2 StatID |a DBCoverage |b SCOPUS |d 2020-08-29 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0300 |2 StatID |a DBCoverage |b Medline |d 2020-08-29 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0320 |2 StatID |a DBCoverage |b PubMed Central |d 2020-08-29 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0600 |2 StatID |a DBCoverage |b Ebsco Academic Search |d 2020-08-29 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0030 |2 StatID |a Peer Review |b ASC |d 2020-08-29 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0199 |2 StatID |a DBCoverage |b Clarivate Analytics Master Journal List |d 2020-08-29 |
| 915 | _ | _ | |0 StatID:(DE-HGF)1030 |2 StatID |a DBCoverage |b Current Contents - Life Sciences |d 2020-08-29 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0160 |2 StatID |a DBCoverage |b Essential Science Indicators |d 2020-08-29 |
| 915 | _ | _ | |0 StatID:(DE-HGF)1050 |2 StatID |a DBCoverage |b BIOSIS Previews |d 2020-08-29 |
| 915 | _ | _ | |0 StatID:(DE-HGF)1110 |2 StatID |a DBCoverage |b Current Contents - Clinical Medicine |d 2020-08-29 |
| 915 | _ | _ | |0 StatID:(DE-HGF)1190 |2 StatID |a DBCoverage |b Biological Abstracts |d 2020-08-29 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0113 |2 StatID |a WoS |b Science Citation Index Expanded |d 2020-08-29 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0150 |2 StatID |a DBCoverage |b Web of Science Core Collection |d 2020-08-29 |
| 915 | _ | _ | |0 StatID:(DE-HGF)9905 |2 StatID |a IF >= 5 |b DIABETES : 2018 |d 2020-08-29 |
| 920 | 1 | _ | |0 I:(DE-He78)D090-20160331 |k D090 ; D090 |l Entwicklungsimmunologie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)D090-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|